J. Fälting

发表

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

L. Lannfelt, M. Ingelsson, C. Möller, 2021, Neurobiology of Disease.

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

K. Blennow, L. Lannfelt, H. Zetterberg, 2020, Neuroscience Letters.

Differential signalling pathways for EGF versus PDGF activation of Erk1/2 MAP kinase and cell proliferation in brown pre-adipocytes.

J. Nedergaard, J. Fälting, Therése E Holmström, 2008, Experimental cell research.

Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.

K. Blennow, H. Zetterberg, C. Möller, 2020, Journal of Parkinson's disease.

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

L. Lannfelt, H. Basun, C. Möller, 2021, Molecular and Cellular Neuroscience.

Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839

Michael D B Swedberg, C. Pollard, M. Bridgland-Taylor, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimer’s Disease*

B. Ploeger, S. Eketjäll, B. Swahn, 2012 .

Evidence for dimeric BACE-mediated APP processing.

U. Lendahl, A. Juréus, K. Kolmodin, 2010, Biochemical and biophysical research communications.

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

K. Blennow, L. Lannfelt, H. Zetterberg, 2020, Neuroscience Letters.

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease*

Britt-Marie Swahn, Bart Ploeger, Tjerk Bueters, 2012, The Journal of Biological Chemistry.

New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.

S. Eketjäll, B. Swahn, K. Kolmodin, 2012, Journal of medicinal chemistry.

In brown adipocytes, adrenergically induced β₁-/β₃-(Gs)-, α₂-(Gi)- and α₁-(Gq)-signalling to Erk1/2 activation is not mediated via EGF receptor transactivation.

J. Nedergaard, J. Fälting, Therése E Holmström, 2013, Experimental cell research.

A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation.

S. Hellberg, E. Mandelkow, R. Köster, 2009, The Journal of clinical investigation.

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

S. Haeberlein, S. Eketjäll, J. Janson, 2016, Journal of Alzheimer's disease : JAD.

Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β‐amyloid levels in the CNS

U. Lendahl, S. Eketjäll, A. Juréus, 2015, Journal of neurochemistry.

AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice

S. Eketjäll, B. Swahn, K. Kolmodin, 2013, The Journal of Neuroscience.

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

S. Hellberg, R. Bhat, P. Arvidsson, 2013, Journal of neurochemistry.

Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig

S. Visser, S. Eketjäll, J. Janson, 2014, Pharmaceutical Research.

How Partnership Should Work to Bring Innovative Medicines to Patients.

A. Maroney, Gunilla Osswald, Marco Giorgetti, 2020, Drug discovery today.

Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy.

Britt-Marie Swahn, Margareta Ek, Johan Lindström, 2012, Bioorganic & medicinal chemistry letters.

Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.

Britt-Marie Swahn, Johan Lindström, Stefan Berg, 2012, Journal of medicinal chemistry.

Combining an amyloid‐beta (Aβ) cleaving enzyme inhibitor with a γ‐secretase modulator results in an additive reduction of Aβ production

R. Cowburn, S. Eketjäll, P. Arvidsson, 2015, The FEBS journal.

Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers

Chi-Ming Lee, E. Sparve, J. Fälting, 2014, Clinical pharmacology in drug development.

Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.

J. Malmström, P. Johansson, A. Kers, 2013, Journal of medicinal chemistry.

Bace Inhibitors for the Treatment of Alzheimer's Disease

S. Eketjäll, B. Swahn, J. Fälting, 2009, Alzheimer's & Dementia.

Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils

L. Lannfelt, M. Ingelsson, C. Möller, 2023, Aging brain.

New aminoimidazoles as beta-secretase (BACE-1) inhibitors showing amyloid-beta (A beta ) lowering in brain.

S. Eketjäll, B. Swahn, K. Strömberg, 2012 .